Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

10.38
-0.3200-2.99%
Post-market: 10.30-0.0800-0.77%19:42 EDT
Volume:220.50K
Turnover:2.29M
Market Cap:63.45M
PE:-0.20
High:10.97
Open:10.61
Low:10.12
Close:10.70
52wk High:309.60
52wk Low:9.10
Shares:6.11M
Float Shares:3.83M
Volume Ratio:0.82
T/O Rate:5.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-51.9692
EPS(LYR):-59.6431
ROE:-783.37%
ROA:-62.39%
PB:-0.67
PE(LYR):-0.17

Loading ...

Gossamer Bio (GOSS) Receives a Hold from Wedbush

TIPRANKS
·
Jul 29

Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target

MT Newswires Live
·
Jul 28

Top Premarket Gainers

MT Newswires Live
·
Jul 28

U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit

Reuters
·
Jul 28

Gossamer Bio Inc : Leerink Partners Raises to Outperform from Market Perform

THOMSON REUTERS
·
Jul 28

Gossamer Bio upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
Jul 28

NASD Most Active Issues

Dow Jones
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS)

TIPRANKS
·
Jul 28

Gossamer Bio Price Target Maintained with a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 28

Gossamer Bio Plans September New Drug Application Submission for Potential Pulmonary Arterial Hypertension Treatment

MT Newswires Live
·
Jul 27

Gossamer Bio Shareholders Approved Convertible Note Exchange Proposals at Special Meeting

Reuters
·
Jul 27

Gossamer Bio - Plans Nda Submission for Seralutinib in Pah in September 2026

THOMSON REUTERS
·
Jul 27

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

THOMSON REUTERS
·
Jul 27

Gossamer Bio - Chiesi to Make One-Time $5 Mln Payment to Gossamer

THOMSON REUTERS
·
Jul 27

Gossamer Bio - Reacquires Worldwide Development and Commercial Rights to Seralutinib from Chiesi

THOMSON REUTERS
·
Jul 27

Gossamer Bio Inc: Co and Chiesi Agreed to Terminate Their Collaboration and License Agreement

THOMSON REUTERS
·
Jul 27

Gossamer Bio Shareholders Approve Charter Amendment Increasing Authorized Common Shares to 4 Billion

Reuters
·
Jul 15

Gossamer Bio announces determination of conversion rate for senior secured notes

TIPRANKS
·
Jul 01

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes Due 2030 and Exercise Price for Purchase Warrants

THOMSON REUTERS
·
Jul 01

Gossamer Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 26